ROCO
4123
Market cap741mUSD
Oct 08, Last price
31.35TWD
1D
0.80%
1Q
-15.50%
Jan 2017
8.25%
IPO
340.31%
Name
Center Laboratories Inc
Chart & performance
P/E
2.54
P/S
15.61
EPS
12.35
Div yield, %
2.43%
Shrs. gr., 5y
3.35%
Rev. gr., 5y
16.16%
Revenues
1.52b
-6.28%
Net income
9.32b
P
CFO
27m
-93.47%
Dividend
Aug 17, 20261.8323 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Center Laboratories, Inc. operates as a Taiwanese pharmaceutical enterprise, with its primary focus lying in the manufacturing and distribution of various medical products across Taiwan. Beyond its core drug operations, the firm is heavily invested in the research and development of both small molecule therapeutics and biologics, including proteins and antibodies. Additionally, its extensive portfolio encompasses pharmaceutical CDMO services, medical devices, nutritional health products, agribiotechnology initiatives, advanced stem cell and immune cell therapies, and even strategic ventures in industry investment funds and venture capital. Founded in 1959, Center Laboratories maintains its headquarters in Taipei, Taiwan.
Key people
An-Ni Mao
Manager of Finance & Accounting · since 2022
Chairman of the Board, Chief Operating Officer, Chief Investment Officer · since 2024
Jui-Pao Hsu
General Manager · since 1998
Chiun-Yu Lin
Plant Manager · since 2017
Qingyu Tang
Corporate Governance Officer · since 2022
Po-Chih Chang
Director · since 2010
Director · since 2020
Chang-Hai Tsai
Director · since 2022
Sheng-Wen Yeh
Director · since 2025
Independent Director · since 2020
Independent Director · since 2010
Li-Wei Kuo
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||